During the past decade, IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II conducted 34 clinical trials. In the 10-year time frame, 34 clinical trials started and 14 clinical trials were completed, i.e. on average, 41.2% percent of trials that started reached the finish line to date. In the past 5 years, 20 clinical trials started and 10 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II" #1 sponsor was "Hoffmann-La Roche" with 31 trials, followed by "EMD Serono Research & Development Institute, Inc." with 3 trials sponsored, "Fondazione Ricerca Traslazionale" with 2 trials sponsored, "Canadian Cancer Trials Group" with 1 trials sponsored and "Genentech, Inc." with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II" #1 collaborator was "AOU S.Orsola Malpighi-Unit of Oncologic Molecular and Transplantations Pathology" with 2 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "AOU S. Orsola Malpighi - Clinical Trial Office" with 1 trials as a collaborator, "Australasian Lung Cancer Trials Group" with 1 trials as a collaborator and "Bioikos Ambiente Srl" with 1 trials as a collaborator. Other collaborators include 19 different institutions and companies that were collaborators in the rest 29 trials.

According to Clinical.Site data, the most researched conditions in "IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II" are "Breast Cancer" (7 trials), "Non-Small Cell Lung Cancer" (5 trials), "Carcinoma, Non-Small-Cell Lung" (4 trials), "Head and Neck Neoplasms" (2 trials) and "Ovarian Cancer" (2 trials). Many other conditions were trialed in "IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II" in a lesser frequency.

Most popular intervention types in "IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II" are "Drug" (40 trials), "Radiation" (3 trials), "Other" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (14 trials), "Placebo" (13 trials), "Paclitaxel" (9 trials), "Carboplatin" (5 trials) and "Bevacizumab" (4 trials). Other intervention names were less common.

The vast majority of trials in "IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II" are 40 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II". undefined are not yet recruiting, 12 are recruiting, 13 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II, 0 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 27 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".